Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

ormularies. Formulary access equal to that of Renagel is expected by the end of the third quarter, ahead of Genzyme's expectations.

Within the Transplant business, second-quarter sales of Thymoglobulin(R) (Anti-thymocyte Globulin [Rabbit]) and Lymphoglobuline(R) (Anti-thymocyte Globulin [Equine]) rose 10 percent to $45.6 million from $41.4 million in the second quarter last year. Worldwide demand for Thymoglobulin continues to grow, and Genzyme is working to build inventory to meet anticipated demand following resolution of a manufacturing issue during 2007 that affected product appearance in some lots. The company has begun construction of a new manufacturing plant for Thymoglobulin in France to support the long-term growth of the product.

Genzyme continues to prepare for the U.S. and European launch of Mozobil next year, and it is also planning to seek regulatory approvals globally. The company anticipates peak annual sales of Mozobil in the transplant setting of $400 million. More than 900 patients have already received the product through a compassionate use program in the United States, and similar compassionate use programs have recently begun in Europe. Genzyme continues to invest in studies exploring additional potential applications for Mozobil, including its use in conjunction with chemotherapy.

Within the Biosurgery business, sales of Synvisc(R) (hylan G-F 20) and Synvisc-ONE rose to $70.9 million from $64.9 million, an increase of 9 percent. The growth was driven by the increasing strength of Synvisc in the U.S. market and the initiation of direct sales of the product in Latin America. Genzyme is introducing Synvisc-ONE in a growing number of European and Southeast Asian countries. The product is designed to simplify osteoarthritis pain management and thereby reach a broader set of patients.

Also within the Biosurgery business, sales of Sepra(R) products have remained consistently strong over recent quarters. Sales rose 39 per
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...   ISN has released its third annual ... publication series. With data aggregated from over eight ... within its online contractor management platform, ISNetworld, this three-part ... (KPI) statistics. The Contractor ... is available in two industry specific volumes: Oil ...
(Date:12/17/2014)... 2014 Achim Noack has been named ... Group. In this position, Noack will assist Jerry Stoller, ... develop marketing strategy and supervise global marketing management and ... has tremendous knowledge and experience in the crop protection ... experience and innovative thinking will be a great asset ...
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Award-winning Palm Vein Recognition Device Helps BayCare ... Records and,Safeguard Patient Privacy, SUNNYVALE, Calif., ... Inc., a leading supplier of innovative computer ... security solutions,today announced that BayCare Health System, ...
... Sept. 23 Endocare, Inc.,(Nasdaq: ENDO ), ... of minimally invasive technologies for tissue and tumor,ablation, ... for the first time posted on its website ... prostate cancer, covering,primary, salvage and focal cryoablation, also ...
... NicOx,S.A. (Euronext Paris: COX) today announced it ... leading producer of two-piece capsules, for,the commercial ... is NicOx, lead investigational product and the ... class of,anti-inflammatory agents. The aim of this ...
Cached Biology Technology:Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 2Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 3Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 4Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 5Best Practices Document on Cryoablation Posted on Website of American Urological Association 2NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules 2NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules 3NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules 4
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... researchers from Michigan State University and the University of Cincinnati ... of Excellence for Parkinson,s disease grant. The grant, from ... National Institutes of Health, makes MSU,s College of Human Medicine ... Two new MSU researchers, Jack Lipton, Ph.D., and Caryl ...
... of invasive ants in northern Australia, finding black holes ... has recognised the outstanding work of some of its ... The CSIRO Medals are awarded each year to staff ... the organisation. Awarded since 1985, the CSIRO Medals have ...
... in human beings. This means laughing at others is also ... being laughed at causes some people enormous problems in their ... affects people in all cultures alike. What is the ... gelotophobia? One of the aims of a study published recently ...
Cached Biology News:MSU becoming center of excellence for Parkinson's research 2CSIRO medal winners 2CSIRO medal winners 3Fear of being laughed at crosses cultural boundaries 2Fear of being laughed at crosses cultural boundaries 3Fear of being laughed at crosses cultural boundaries 4
Ms anti-Cyclophilin D...
... to qualitatively detect EGFR ... paraffin-embedded (FFPE) tissue sections, ... cell preparations, using Chromogenic ... Fluorescent In Situ Hybridization ...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Biology Products: